Showing results (11-20 of 26,432) with videos related to
Sort By:
Pageof 2,644
European Journal of Drug Metabolism and Pharmacokinetics|June 3, 2022
An Open Label, Phase 1, Randomized, Seven-treatment, Seven-period, Crossover Study to Assess the Relative Bioavailability, pH Effect, Food Effect, and Dose Proportionality of CC-292, a Potent and Orally Available Bruton's Tyrosine Kinase InhibitorYiming Cheng, Liangang Liu, Yongjun Xue, et al.European Journal of Drug Metabolism and Pharmacokinetics|March 24, 2024
A Phase I, Open-Label, Mass Balance Study of [14C]-Iberdomide in Healthy SubjectsYiming Cheng, Xiaomin Wang, Liangang Liu, et al.Journal of Clinical Pharmacology|March 13, 2024
Integrating Full Bayesian Inference and Student's t-Distribution Method for Enhanced Outlier Handling in Caffeine Population Pharmacokinetics: Assessing Drug-Drug Interactions with Enasidenib in Relapsed or Refractory AML and MDS PatientsYiming Cheng, Shengnan Du, Hongxiang Hu, et al.Journal of Clinical Pharmacology|April 2, 2024
Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeYiming Cheng, Xiaomin Wang, Atalanta Ghosh, et al.Journal of Clinical Pharmacology|October 7, 2021
Assessment of Transporter-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients With Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeYiming Cheng, Xiaomin Wang, Zeen Tong, et al.Ejhaem|September 2, 2022
Aiding early clinical drug development by elucidation of the relationship between tumor growth inhibition and survival in relapsed/refractory multiple myeloma patientsYiming Cheng, Kevin Hong, Nianhang Chen, et al.Journal of Pharmaceutical Sciences|January 27, 2025
A population pharmacokinetic analysis to evaluate the impact of renal impairment on the pharmacokinetics of iberdomidePing Chen, Hongxia Lin, Yongjun Xue, et al.British Journal of Clinical Pharmacology|August 18, 2022
Model-based analysis for the population pharmacokinetics of iberdomide and its major active metabolite in healthy subjects and patients with relapsed and refractory multiple myelomaYiming Cheng, Yongjun Xue, Lu Chen, et al.Clinical Pharmacology : Advances and Applications|March 7, 2023
A Phase 1, Multicenter, Open-Label Study to Evaluate the Pharmacokinetics of Iberdomide in Subjects with Mild, Moderate, or Severe Hepatic Impairment Compared with Healthy SubjectsYiming Cheng, Ying Ye, Allison Gaudy, et al.The AAPS Journal|April 29, 2025
Model-informed Drug Development (MIDD) Approach to Support Biopharmaceutical Development of IberdomideCaroline Sychterz, Ping Chen, Ajay Saxena, et al.Pageof 2,644